{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T20:22:53Z","timestamp":1787430173250,"version":"build-2736575974"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jcf.2026.08.005","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T19:30:28Z","timestamp":1787427028000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prenatal CFTR modulator therapy and fetal meconium ileus in cystic fibrosis: a systematic review and individual patient data meta-analysis"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6231-2251","authenticated-orcid":false,"given":"Vincenzo G","family":"Menditto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Pomponio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Caporelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marica","family":"Bordicchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Boni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco Bruno Luigi","family":"Rocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Menditto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Fabrizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 2","key":"10.1016\/j.jcf.2026.08.005_bib0001","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/j.jcf.2017.06.007","article-title":"Meconium ileus in cystic fibrosis","volume":"16","author":"Sathe","year":"2017","journal-title":"J Cyst Fibros"},{"issue":"11","key":"10.1016\/j.jcf.2026.08.005_bib0002","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.3390\/diagnostics14111179","article-title":"Diagnosis and management of simple and complicated meconium ileus in cystic fibrosis, a systematic review","volume":"14","author":"Donos","year":"2024","journal-title":"Diagnostics (Basel)"},{"issue":"19","key":"10.1016\/j.jcf.2026.08.005_bib0003","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"10212","key":"10.1016\/j.jcf.2026.08.005_bib0004","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jcf.2026.08.005_bib0005","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/ajrccm\/aamaf001","article-title":"Elexacaftor\/Tezacaftor\/Ivacaftor for cystic fibrosis and rare CFTR variants: in vitro translation to a phase 3, double-blind, randomized, placebo-controlled trial and real-world study","volume":"212","author":"Castellani","year":"2026","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.jcf.2026.08.005_bib0006","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.chest.2024.09.019","article-title":"Impact of cystic Fibrosis transmembrane conductance regulator modulators on maternal outcomes during and after pregnancy","volume":"167","author":"Jain","year":"2025","journal-title":"Chest"},{"issue":"485","key":"10.1016\/j.jcf.2026.08.005_bib0007","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau7531","article-title":"In utero and postnatal VX-770 administration rescues multiorgan disease in a ferret model of cystic fibrosis","volume":"11","author":"Sun","year":"2019","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.jcf.2026.08.005_bib0008","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jcf.2024.09.007","article-title":"CF ferrets exposed to in utero ivacaftor do not develop lens abnormalities","volume":"24","author":"Taylor-Cousar","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"21","key":"10.1016\/j.jcf.2026.08.005_bib0009","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1001\/jama.2023.8120","article-title":"Cystic fibrosis: a review","volume":"329","author":"Ong","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jcf.2026.08.005_bib0010","article-title":"A foetus with cystic fibrosis - to treat or not to treat?","volume":"83","author":"Padmakumar","year":"2023","journal-title":"Respir Med Res"},{"issue":"3","key":"10.1016\/j.jcf.2026.08.005_bib0011","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/pd.70098","article-title":"Translating emerging data for fetal treatment of cystic fibrosis","volume":"46","author":"Zaretsky","year":"2026","journal-title":"Prenat Diagn"},{"issue":"1","key":"10.1016\/j.jcf.2026.08.005_bib0012","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S2213-2600(25)00430-8","article-title":"How early should CFTR modulators be initiated to prevent structural cystic fibrosis lung disease?","volume":"14","author":"Woods","year":"2026","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1016\/j.jcf.2026.08.005_bib0013","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jcf.2021.12.004","article-title":"Drug exposure to infants born to mothers taking Elexacaftor, Tezacaftor, and Ivacaftor","volume":"21","author":"Collins","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.08.005_bib0014","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jcf.2026.08.005_bib0015","first-page":"223","article-title":"The CARE guidelines: consensus-based clinical case reporting guideline development","volume":"7","author":"Gagnier","year":"2013","journal-title":"BMJ Case Rep"},{"issue":"7624","key":"10.1016\/j.jcf.2026.08.005_bib0016","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"335","author":"von Elm","year":"2007","journal-title":"BMJ"},{"key":"10.1016\/j.jcf.2026.08.005_bib0017","author":"Wells"},{"issue":"2","key":"10.1016\/j.jcf.2026.08.005_bib0018","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/jebm.12427","article-title":"The ROBINS-I and the NOS had similar reliability but differed in applicability: a random sampling observational studies of systematic reviews\/meta-analysis","volume":"14","author":"Zhang","year":"2021","journal-title":"J Evid Based Med"},{"key":"10.1016\/j.jcf.2026.08.005_bib0019","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.jcf.2026.08.005_bib0020","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.jcf.2025.03.006","article-title":"CFTR modulator therapy via carrier mother to treat meconium ileus in a F508del homozygous fetus: insights from an unsuccessful case","volume":"24","author":"Destoop","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2026.08.005_bib0021","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jcf.2025.03.009","article-title":"First real-world study of fetal therapy with CFTR modulators in cystic fibrosis: report from the MODUL-CF study","volume":"24","author":"Bonnel","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2026.08.005_bib0022","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jcf.2024.11.011","article-title":"Outcomes of prenatal use of elexacaftor\/tezacaftor\/ivacaftor in carrier mothers to treat meconium ileus in fetuses with cystic fibrosis","volume":"24","author":"Metcalf","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2026.08.005_bib0023","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.71168","article-title":"Prenatal Elexacaftor\/Tezacaftor\/Ivacaftor treatment prevents meconium ileus, but not exocrine pancreatic insufficiency and lung disease in infants with cystic fibrosis","volume":"60","author":"Aleksander","year":"2025","journal-title":"Pediatr Pulmonol"},{"issue":"4","key":"10.1016\/j.jcf.2026.08.005_bib0024","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jcf.2022.04.005","article-title":"A case report of CFTR modulator administration via carrier mother to treat meconium ileus in a F508del homozygous fetus","volume":"21","author":"Szentpetery","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcf.2026.08.005_bib0025","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000530261","article-title":"Prenatal cystic fibrosis transmembrane conductance regulator modulator therapy: a promising way to change the impact of Cystic fibrosis","volume":"50","author":"G\u00f3mez-Montes","year":"2023","journal-title":"Fetal Diagn Ther"},{"issue":"5","key":"10.1016\/j.jcf.2026.08.005_bib0026","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jcf.2021.03.018","article-title":"Normal pancreatic function and false-negative CF newborn screen in a child born to a mother taking CFTR modulator therapy during pregnancy","volume":"20","author":"Fortner","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"S2","key":"10.1016\/j.jcf.2026.08.005_bib0027","article-title":"FTR-modulator therapy during pregnancy in a mother with F508del carrier status and high-grade suspicion of cystic fibrosis in the foetus","volume":"22","author":"Thee","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"S2","key":"10.1016\/j.jcf.2026.08.005_bib0028","doi-asserted-by":"crossref","first-page":"S235","DOI":"10.1016\/S1569-1993(25)02037-5","article-title":"Outcomes in first year of life for infants with exposure to elexacaftor\/tezacaftor\/ivacaftor (ETI) in utero","volume":"24","author":"Green","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"7","key":"10.1016\/j.jcf.2026.08.005_bib0029","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.7326\/L23-0112","article-title":"Treatment of fetal cystic fibrosis with cystic fibrosis transmembrane conductance regulator modulation therapy","volume":"176","author":"Blumenfeld","year":"2023","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jcf.2026.08.005_bib0030","first-page":"1","article-title":"Intrauterine treatment in two fetuses affected by cystic fibrosis: to whom and since when? Report of cases","author":"Mart\u00ednez S\u00e1nchez","year":"2025","journal-title":"Fetal Diagn Ther"},{"issue":"6","key":"10.1016\/j.jcf.2026.08.005_bib0031","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.jcf.2025.07.015","article-title":"PRenatal mOdulator treatment to PrEvent CF complicaTions (PROTECT) workshop report","volume":"24","author":"Szentpetery","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2026.08.005_bib0032","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jcf.2025.11.013","article-title":"Pharmacokinetic assessment of elexacaftor\/tezacaftor\/ivacaftor and their metabolites in maternal blood, cord blood, the neonate, and breastmilk of a cystic fibrosis carrier mother\/affected fetus dyad","volume":"25","author":"Sinkey","year":"2026","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.jcf.2026.08.005_bib0033","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.jcf.2024.06.003","article-title":"Clinical outcomes of two infants with cystic fibrosis, including presence of the vas deferens, born to a woman with cystic fibrosis taking CFTR modulators during both pregnancies","volume":"23","author":"Kowalik","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2026.08.005_bib0034","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jcf.2025.01.012","article-title":"Monitoring ETI effects over 1.7 years in an infant treated in utero, via breast milk and granules by repeated faecal elastase measurements","volume":"24","author":"Appelt","year":"2025","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.08.005_bib0035","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.jcf.2026.02.001","article-title":"Prenatal initiation of elexacaftor\/tezacaftor\/ivacaftor via carrier mother prevents congenital bilateral absence of vas deferens in a male infant with cystic fibrosis","volume":"25","author":"Thee","year":"2026","journal-title":"J Cyst Fibros"},{"issue":"S1","key":"10.1016\/j.jcf.2026.08.005_bib0036","article-title":"Sermet Gaudelus I. First report of continuous administration of elexacaftor\/tezacaftor\/ivacaftor from in utero to 1 year of age","volume":"24","author":"Monrad","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.jcf.2026.08.005_bib0038","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/MPG.0b013e3181bb3427","article-title":"Clinical and genetic characteristics of meconium ileus in newborns with and without cystic fibrosis","volume":"50","author":"Gorter","year":"2010","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"6","key":"10.1016\/j.jcf.2026.08.005_bib0039","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jcf.2019.07.003","article-title":"Risk factors for adverse outcome in infancy in meconium ileus cystic fibrosis infants: a multicentre Italian study","volume":"18","author":"Padoan","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2026.08.005_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpedsurg.2025.162545","article-title":"University of California Fetal Consortium. Meconium-related obstruction: contemporary experience in a multi-institutional consortium","volume":"61","author":"Rook","year":"2026","journal-title":"J Pediatr Surg"},{"issue":"8","key":"10.1016\/j.jcf.2026.08.005_bib0041","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.jpedsurg.2021.02.047","article-title":"Early management of meconium ileus in infants with cystic fibrosis: a prospective population cohort study","volume":"56","author":"Long","year":"2021","journal-title":"J Pediatr Surg"},{"issue":"1","key":"10.1016\/j.jcf.2026.08.005_bib0042","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jpedsurg.2008.10.010","article-title":"Neonatal outcomes associated with intestinal abnormalities diagnosed by fetal ultrasound","volume":"44","author":"Ruiz","year":"2009","journal-title":"J Pediatr Surg"},{"issue":"1","key":"10.1016\/j.jcf.2026.08.005_bib0043","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/ijns9010010","article-title":"Immunoreactive trypsinogen in infants born to women with cystic fibrosis taking Elexacaftor-Tezacaftor-Ivacaftor","volume":"9","author":"Patel","year":"2023","journal-title":"Int J Neonatal Screen"},{"issue":"1","key":"10.1016\/j.jcf.2026.08.005_bib0044","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jcf.2024.11.014","article-title":"Lens-related ocular changes in fetal rats following in-utero exposure to elexacaftor-tezacaftor-ivacaftor","volume":"24","author":"Zhu","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2026.08.005_bib0045","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jcf.2024.09.007","article-title":"CF ferrets exposed to in utero ivacaftor do not develop lens abnormalities","volume":"24","author":"Taylor-Cousar","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2026.08.005_bib0046","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.jcf.2022.10.004","article-title":"Congenital bilateral cataracts in newborns exposed to elexacaftor-tezacaftor-ivacaftor in utero and while breast feeding","volume":"21","author":"Jain","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2026.08.005_bib0047","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.jcf.2024.01.001","article-title":"Drug-induced liver injury associated with elexacaftor\/tezacaftor\/ivacaftor: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS)","volume":"23","author":"Shi","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2026.08.005_bib0048","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jcf.2021.03.006","article-title":"Maternal and fetal outcomes following elexacaftor- tezacaftor-ivacaftor use during pregnancy and lactation","volume":"20","author":"Taylor-Cousar","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.jcf.2026.08.005_bib0049","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.jcf.2023.03.014","article-title":"A multidisciplinary model for prenatal care for patients with cystic fibrosis in the era of highly effective modulator therapy","volume":"22","author":"Li","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2026.08.005_bib0050","article-title":"Prospectively evaluating maternal and fetal outcomes in the era of CFTR modulators: the MAYFLOWERS observational clinical trial study design","volume":"9","author":"Jain","year":"2022","journal-title":"BMJ Open Respir Res"},{"issue":"6","key":"10.1016\/j.jcf.2026.08.005_bib0051","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1097\/AOG.0000000000001485","article-title":"Refusal of medically recommended treatment during pregnancy","volume":"127","year":"2016","journal-title":"Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.jcf.2026.08.005_bib0052","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jcf.2022.05.014","article-title":"Editorial - the ethical implications of treating a pregnant woman to benefit the fetus","volume":"21","author":"Bennett","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2026.08.005_bib0053","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1002\/ppul.26954","article-title":"International disparities in diagnosis and treatment access for cystic fibrosis","volume":"59","author":"Guo","year":"2024","journal-title":"Pediatr Pulmonol"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326037197?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326037197?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T19:30:36Z","timestamp":1787427036000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199326037197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":52,"alternative-id":["S1569199326037197"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2026.08.005","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prenatal CFTR modulator therapy and fetal meconium ileus in cystic fibrosis: a systematic review and individual patient data meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2026.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}